Inhaled Salmeterol

[1]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[2]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[3]  B. Penninx,et al.  Determinants of different dimensions of disease severity in asthma and COPD : pulmonary function and health-related quality of life. , 2001, Chest.

[4]  S. Sullivan,et al.  The costs of treating COPD in the United States. , 2001, Chest.

[5]  P M Calverley,et al.  Health status deterioration in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[6]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[7]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[8]  M. Cazzola,et al.  Additive effects of salmeterol and fluticasone or theophylline in COPD. , 2000, Chest.

[9]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[10]  D. Coultas,et al.  Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. , 2000, Archives of internal medicine.

[11]  P. Weiner,et al.  The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. , 2000, Chest.

[12]  N. Pride,et al.  Recent trends in physician diagnosed COPD in women and men in the UK , 2000, Thorax.

[13]  D. Strachan,et al.  Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease? , 2000, Thorax.

[14]  A. Tattersfield,et al.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects , 2000, Thorax.

[15]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[16]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[17]  D. Niewoehner,et al.  Relation of FEV1 to Clinical Outcomes during Exacerbations of Chronic Obstructive Pulmonary Disease , 2000 .

[18]  M. Cazzola,et al.  Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease , 1999, Thorax.

[19]  M. R. Mölken,et al.  An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. , 1999, Thorax.

[20]  O. Kayacan,et al.  Formoterol and Salmeterol in Partially Reversible Chronic Obstructive Pulmonary Disease: A Crossover, Placebo-Controlled Comparison of Onset and Duration of Action , 1999, Respiration.

[21]  N. Gross,et al.  Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. , 1999, American journal of respiratory and critical care medicine.

[22]  P. Paggiaro,et al.  Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. , 1999, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[23]  M. Cazzola,et al.  Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease , 1999, Thorax.

[24]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[25]  M. Cazzola,et al.  Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? , 1999, Respiratory medicine.

[26]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[27]  J. Guest.  The Annual Cost of Chronic Obstructive Pulmonary Disease to the UK’s National Health Service , 1999 .

[28]  A. Tattersfield,et al.  The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. , 1999, The European respiratory journal.

[29]  M. Cazzola,et al.  Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease , 1999, European Journal of Clinical Pharmacology.

[30]  L. Squassante,et al.  Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease , 1998 .

[31]  P. Argyropoulou,et al.  Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[32]  R. Irwin,et al.  Chronic obstructive pulmonary disease , 1998, The Lancet.

[33]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[34]  M. Cazzola,et al.  Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[35]  N. Dunn,et al.  Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2 agonists , 1998, Thorax.

[36]  M. Cazzola,et al.  Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. , 1998, The European respiratory journal.

[37]  S. Durante,et al.  Short-term cardiovascular effects of salmeterol. , 1998, Chest.

[38]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[39]  M. Tsukino,et al.  Health-related quality of life in patients with chronic obstructive pulmonary disease. , 1998, Current opinion in pulmonary medicine.

[40]  M. Cazzola,et al.  A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[41]  A. Ramírez-Venegas,et al.  Salmeterol reduces dyspnea and improves lung function in patients with COPD. , 1997, Chest.

[42]  D. McTavish,et al.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. , 1997, Drugs.

[43]  A. Tattersfield,et al.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. , 1997, Thorax.

[44]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[45]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[46]  T. Petty,et al.  Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute Workshop Summary. Bethesda, Maryland, August 29-31, 1995. , 1997, JAMA.

[47]  M. Cazzola,et al.  A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. , 1996, Respiratory medicine.

[48]  B. Lipworth,et al.  Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. , 1996, Thorax.

[49]  R. Mann,et al.  Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. , 1996, Journal of clinical epidemiology.

[50]  M. Cazzola,et al.  A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. , 1995, Pulmonary pharmacology.

[51]  B. Celli.  Pulmonary rehabilitation in patients with COPD. , 1995, American journal of respiratory and critical care medicine.

[52]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[53]  C. Ulrik.  Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. , 1995, Thorax.

[54]  M. Cazzola,et al.  Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. , 1995, Respiratory medicine.

[55]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[56]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[57]  J. Karpel,et al.  A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. , 1994, Chest.

[58]  M. Cazzola,et al.  Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. , 1994, Pulmonary pharmacology.

[59]  H. Magnussen,et al.  Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. , 1994, The European respiratory journal.

[60]  C. van Weel,et al.  Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life. , 1992, Chest.

[61]  A. Woodcock,et al.  Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. , 1992, The European respiratory journal.

[62]  J. Maconochie,et al.  Dose-response study with high-dose inhaled salmeterol in healthy subjects. , 1992, British journal of clinical pharmacology.

[63]  J. Stewart,et al.  Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. , 1992, Chest.

[64]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[65]  Anthonisen Nr,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986 .